Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL VALERATE AND DIENOGEST versus PREMPHASE 14 14.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL VALERATE AND DIENOGEST versus PREMPHASE 14 14.
ESTRADIOL VALERATE AND DIENOGEST vs PREMPHASE 14/14
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol valerate is a prodrug of estradiol, an estrogen that binds to estrogen receptors (ERα and ERβ) to regulate gene transcription, promoting endometrial growth and suppressing gonadotropins. Dienogest is a progestin with partial antiandrogenic activity, binding to progesterone receptors to inhibit endometrial proliferation and ovulation, and reducing androgen synthesis.
Conjugated estrogens (CE) bind to estrogen receptors (ERα and ERβ), modulating gene transcription and non-genomic signaling pathways to induce estrogenic effects. Medroxyprogesterone acetate (MPA) is a progestin that binds to progesterone receptors, suppressing endometrial proliferation and counteracting estrogen-induced endometrial hyperplasia. The combination provides hormone replacement therapy with reduced risk of endometrial cancer.
One tablet (2 mg estradiol valerate and 3 mg dienogest) once daily orally, without interruption, following the first day of menstrual cycle.
One tablet orally once daily, each tablet contains conjugated estrogens 0.625 mg and medroxyprogesterone acetate 5 mg.
None Documented
None Documented
Estradiol valerate: Terminal half-life of estradiol is 13-15 hours; valerate ester is rapidly hydrolyzed, so systemic estradiol half-life applies. Dienogest: Terminal half-life ~8-10 hours, increasing to ~12-14 hours with multiple dosing due to competitive inhibition of CYP3A4.
Conjugated estrogens have a terminal elimination half-life of 12-24 hours for conjugated equine estrogens; medroxyprogesterone acetate has a half-life of 12-17 hours. Steady-state is reached within 5-7 days.
Estradiol valerate: Renal (primarily as glucuronide and sulfate conjugates) ~40%, Fecal ~60%. Dienogest: Renal ~60% (mostly unchanged), Fecal ~30%.
Conjugated estrogens are excreted primarily in urine (≥90%) as glucuronide and sulfate conjugates; medroxyprogesterone acetate is extensively metabolized and excreted in urine (≤60%) and feces (≤30%) as metabolites.
Category D/X
Category C
Estrogen
Estrogen/Progestin Combination